Clinical Trial Detail

NCT ID NCT03639948
Title Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Kansas Medical Center
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.